Unknown

Dataset Information

0

Can We Treat Secondary Progressive Multiple Sclerosis Now?

ABSTRACT: Secondary progressive multiple sclerosis (SPMS) is characterized by progressive accumulation of disability without intermittent recovery. Treatment of these patients is challenging due to limited understanding of pathogenesis and fewer therapeutic options. This article summarizes difficulties in defining and conducting trials in SPMS, review major clinical trials on therapies approved and unapproved in SPMS and lastly, therapies in pipeline for use in SPMS.

SUBMITTER: Bhatia R 

PROVIDER: S-EPMC6472227 | biostudies-literature | 2019 Apr-Jun

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Can We Treat Secondary Progressive Multiple Sclerosis Now?

Bhatia Rohit R   Singh Nishita N  

Annals of Indian Academy of Neurology 20190401 2

Secondary progressive multiple sclerosis (SPMS) is characterized by progressive accumulation of disability without intermittent recovery. Treatment of these patients is challenging due to limited understanding of pathogenesis and fewer therapeutic options. This article summarizes difficulties in defining and conducting trials in SPMS, review major clinical trials on therapies approved and unapproved in SPMS and lastly, therapies in pipeline for use in SPMS. ...[more]

Similar Datasets

Unknown Elevated sCD40L in Secondary Progressive Multiple Sclerosis in Comparison to Non-progressive Benign and Relapsing Remitting Multiple Sclerosis.
| S-EPMC8552403 | biostudies-literature
Unknown Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies.
| S-EPMC6077906 | biostudies-other
Transcriptomics Novel Biomarkers and Interferon Signature in Secondary Progressive Multiple Sclerosis
2024-03-07 | GSE247181 | GEO
Unknown Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis.
| S-EPMC5497536 | biostudies-literature
Unknown Beta-interferon exposure and onset of secondary progressive multiple sclerosis.
| S-EPMC5008210 | biostudies-literature
Unknown Guanidinoacetate-creatine in secondary progressive multiple sclerosis: a case report.
| S-EPMC8753084 | biostudies-literature
Unknown Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis.
| S-EPMC8414818 | biostudies-literature
Unknown Progressive multiple sclerosis.
| S-EPMC4425257 | biostudies-other
Unknown The Rise and Fall of High-Dose Biotin to Treat Progressive Multiple Sclerosis.
| S-EPMC7609671 | biostudies-literature
Unknown Patients' Experiences in Transitioning to Secondary Progressive Multiple Sclerosis: Qualitative Interviews.
| S-EPMC8571456 | biostudies-literature